VelosBio Inc. is a privately held, US-based, near-term clinical-stage biopharmaceutical company focused on novel cancer targets. The company was founded in 2017 and has an investor syndicate that includes Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures, and Takeda Ventures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/01/18 | $58,000,000 | Series A |
Arix Bioscience Chiesi Ventures Decheng Capital Pappas Ventures Sofinnova Ventures Takeda Pharmaceutical Company | undisclosed |
| 07/09/20 | $137,000,000 | Series B |
Adage Capital Management Cormorant Asset Management Farallon Capital Management Janus Henderson Investors Logos Capital Matrix Capital Management OrbiMed Advisors Surveyor Capital T. Rowe Price Associates Venrock Viking Global Investors Wellington Management Company | undisclosed |
